文献速递头颈部肿瘤放疗

EGFR扩增联合基因表达谱预测头颈鳞癌放疗联合EGFR抑制的疗效:10种异种移植瘤临床前试验

EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models.
PubMed 文献 · Radiother Oncol · 2017-08-11

该临床前试验在10种人头颈鳞癌异种移植瘤中研究分次放疗联合西妥昔单抗的疗效,局部肿瘤控制与EGFR基因扩增及放疗反应相关基因表达谱相关。6/10肿瘤模型联合治疗组局部控制显著优于单纯放疗,其中3个应答模型存在EGFR扩增;基因表达谱可区分EGFR扩增与非扩增及联合治疗应答与非应答肿瘤。EGFR扩增状态联合基因表达谱可能作为个体化联合治疗的预测生物标志物,需临床验证。

要点

  • 10种HNSCC异种移植瘤中6种对西妥昔单抗联合分次放疗的局部控制显著优于单纯放疗。
  • 6个应答模型中3个存在EGFR基因扩增。
  • EGFR扩增状态联合基因表达谱可能预测联合治疗应答,尚需临床验证。

核心结论

  • EGFR扩增状态联合基因表达谱可能作为西妥昔单抗联合分次放疗的预测生物标志物,需进一步临床验证。

研究设计与样本

  • 临床前试验,在10种人头颈鳞癌异种移植瘤中体内及离体研究分次放疗联合EGFR抑制的效果。
  • 局部肿瘤控制于放疗结束后120天评估,比较单纯分次放疗(30次,6周)与同步西妥昔单抗联合放疗。
  • EGFR基因扩增状态用FISH检测,基因表达分析采用自建基因面板。

主要发现

  • 10种肿瘤模型中6种联合西妥昔单抗与分次放疗较单纯放疗局部肿瘤控制显著提高。
  • 6个应答模型中有3个可检测到EGFR基因扩增。
  • 未治疗肿瘤的基因表达谱在EGFR扩增与非扩增肿瘤间、以及联合治疗应答与非应答肿瘤间均存在显著差异。

关键数值与推荐

  • 局部肿瘤控制评估时间点为放疗结束后120天。
  • 分次放疗方案为30次、6周。
  • EGFR基因扩增状态采用FISH检测。

临床怎么用

  • EGFR扩增状态联合基因表达谱有望用于筛选适合西妥昔单抗联合分次放疗的头颈鳞癌患者,但目前仅为临床前证据,需临床验证后应用。

局限性

  • 本研究为临床前异种移植瘤试验,结果需临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Improvement of the results of radiotherapy by EGFR inhibitors is modest, suggesting significant intertumoural heterogeneity of response. To identify potential biomarkers, a preclinical trial was performed on ten different human squamous cell carcinoma xenografts of the head and neck (HNSCC) studying in vivo and ex vivo the effect of fractionated irradiation and EGFR inhibition. Local tumour control and tumour growth delay were correlated with potential biomarkers, e.g. EGFR gene amplification and radioresponse-associated gene expression profiles. MATERIAL AND METHODS: Local tumour control 120days after end of irradiation was determined for fractionated radiotherapy alone (30f, 6weeks) or after simultaneous EGFR-inhibition with cetuximab. The EGFR gene amplification status was determined using FISH. Gene expression analyses were performed using an in-house gene panel. RESULTS: Six out of 10 investigated tumour models showed a significant increase in local tumour control for the combined treatment of cetuximab and fractionated radiotherapy compared to irradiation alone. For 3 of the 6 responding tumour models, an amplification of the EGFR gene could be demonstrated. Gene expression profiling of untreated tumours revealed significant differences between amplified and non-amplified tumours as well as between responder and non-responder tumours to combined radiotherapy and cetuximab. CONCLUSION: The EGFR amplification status, in combination with gene expression profiling, may serve as a predictive biomarker for personalized interventional strategies regarding combined treatment of cetuximab and fractionated radiotherapy and should, as a next step, be clinically validated.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Koi L, Löck S, Linge A, et al. EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. Radiother Oncol. 2017. PMID: 28807520. doi:10.1016/j.radonc.2017.07.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。